Evaluation of plasma levels of BDNF in patients with disorder depressive
Introduction According to the World Health Organization (WHO, 2017) depressive disorder continues to be the most widespread and growing mental illness in the world, also assumes that in 2020 depression will have a prevalence equal to one in six individuals. Studies of neuroanatomy have highlighted...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2021-04-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933821008981/type/journal_article |
| _version_ | 1797616194189000704 |
|---|---|
| author | D. Galletta C. Mazzarino G. Cusumano A. Santoro |
| author_facet | D. Galletta C. Mazzarino G. Cusumano A. Santoro |
| author_sort | D. Galletta |
| collection | DOAJ |
| description |
Introduction
According to the World Health Organization (WHO, 2017) depressive disorder continues to be the most widespread and growing mental illness in the world, also assumes that in 2020 depression will have a prevalence equal to one in six individuals. Studies of neuroanatomy have highlighted structural alterations in the hippocampus, striatal nuclei and prefrontal cortex in patients with mood disorders. This alteration in depressed patients is closely related to the secretion of neurotrophic factors, in particular there is a reduction in BDNF (Brain Derived Neurotrophic Factor).
Objectives
The objective of this study is to demonstrate which treatments are effective in reducing depressive symptoms that allow the increase of BDNF and consequently the structural homostaticity of the brain.
Methods
We have selected data from the literature of the last decade, collected on major search engines such as: Google Scholar, Research Gate, PubMed, Ebsco. Articles collected by selecting the following Keyword: depression, BDNF (Brain Derived Neurotrophic Factor), neuroimaging cognitive behavior therapy.
Results
The results show that in patients treated with a single drug treatment or vagus nerve stimulation, repetitive transcranial magnetic stimulation (Lang et al., 2008) or electroconvulsive therapy had improvements in BDNF levels, although compared to drug treatment there are problems of no responders, no compliance and lack of effectiveness in reducing vulnerability to relapse. In addition, the study has shown that patients treated with cognitive behavioral therapy have reported greater changes in the frontal and temporal cortex reducing both depressive symptoms and the risk of relapse.
Conclusions
Underlines the importance of an integrated approach
|
| first_indexed | 2024-03-11T07:37:56Z |
| format | Article |
| id | doaj.art-3e2ad3fe50a64736a485a7d1b0c6d791 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:37:56Z |
| publishDate | 2021-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-3e2ad3fe50a64736a485a7d1b0c6d7912023-11-17T05:09:12ZengCambridge University PressEuropean Psychiatry0924-93381778-35852021-04-0164S335S33510.1192/j.eurpsy.2021.898Evaluation of plasma levels of BDNF in patients with disorder depressiveD. Galletta0C. Mazzarino1G. Cusumano2A. Santoro3Department Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, ItalyDepartment Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, ItalyDepartment Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, ItalyDepartment Of Head-neck Care Unit Of Psychiatry And Psychology “federico Ii” University Hospital Naples, “Federico II” University Hospital Naples, Italy, Naples, Italy Introduction According to the World Health Organization (WHO, 2017) depressive disorder continues to be the most widespread and growing mental illness in the world, also assumes that in 2020 depression will have a prevalence equal to one in six individuals. Studies of neuroanatomy have highlighted structural alterations in the hippocampus, striatal nuclei and prefrontal cortex in patients with mood disorders. This alteration in depressed patients is closely related to the secretion of neurotrophic factors, in particular there is a reduction in BDNF (Brain Derived Neurotrophic Factor). Objectives The objective of this study is to demonstrate which treatments are effective in reducing depressive symptoms that allow the increase of BDNF and consequently the structural homostaticity of the brain. Methods We have selected data from the literature of the last decade, collected on major search engines such as: Google Scholar, Research Gate, PubMed, Ebsco. Articles collected by selecting the following Keyword: depression, BDNF (Brain Derived Neurotrophic Factor), neuroimaging cognitive behavior therapy. Results The results show that in patients treated with a single drug treatment or vagus nerve stimulation, repetitive transcranial magnetic stimulation (Lang et al., 2008) or electroconvulsive therapy had improvements in BDNF levels, although compared to drug treatment there are problems of no responders, no compliance and lack of effectiveness in reducing vulnerability to relapse. In addition, the study has shown that patients treated with cognitive behavioral therapy have reported greater changes in the frontal and temporal cortex reducing both depressive symptoms and the risk of relapse. Conclusions Underlines the importance of an integrated approach https://www.cambridge.org/core/product/identifier/S0924933821008981/type/journal_articleDepressive Disorderplasma levelBDNF |
| spellingShingle | D. Galletta C. Mazzarino G. Cusumano A. Santoro Evaluation of plasma levels of BDNF in patients with disorder depressive European Psychiatry Depressive Disorder plasma level BDNF |
| title | Evaluation of plasma levels of BDNF in patients with disorder depressive |
| title_full | Evaluation of plasma levels of BDNF in patients with disorder depressive |
| title_fullStr | Evaluation of plasma levels of BDNF in patients with disorder depressive |
| title_full_unstemmed | Evaluation of plasma levels of BDNF in patients with disorder depressive |
| title_short | Evaluation of plasma levels of BDNF in patients with disorder depressive |
| title_sort | evaluation of plasma levels of bdnf in patients with disorder depressive |
| topic | Depressive Disorder plasma level BDNF |
| url | https://www.cambridge.org/core/product/identifier/S0924933821008981/type/journal_article |
| work_keys_str_mv | AT dgalletta evaluationofplasmalevelsofbdnfinpatientswithdisorderdepressive AT cmazzarino evaluationofplasmalevelsofbdnfinpatientswithdisorderdepressive AT gcusumano evaluationofplasmalevelsofbdnfinpatientswithdisorderdepressive AT asantoro evaluationofplasmalevelsofbdnfinpatientswithdisorderdepressive |